New biosimilar aims to match keytruda in fighting advanced melanoma
NCT ID NCT07475572
First seen Apr 09, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study compares a new drug, AVT32-DRL_PB (a biosimilar to Keytruda), with Keytruda itself in people with stage IIB/C or III melanoma that has been fully removed by surgery. About 120 adults will receive either the biosimilar or Keytruda every 3 weeks for up to 6 cycles. The goal is to see if the biosimilar works just as well and is as safe as the original drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.